Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated August 8, 2024, please find enclosed the transcript of the Earnings Call for the Q1 FY25, held on Wednesday, August 14, 2024 at 8.30 a.m. (IST). Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith extracts of the Unaudited Financial Results of the Company for the quarter ended June 30, 2024, as published in the newspapers viz. "Financial Express" and "Loksatta" on August 15, 2024. Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our intimation dated August 8, 2024, regarding earnings call, the audio recording of the call held today is available on our website. Emcure Pharmaceuticals Ltd - 544210 - Outcome Of Board Meeting Held On August 13, 2024
Outcome of Board Meeting held on August 13, 2024 Emcure Pharmaceuticals Ltd - 544210 - Outcome Of Board Meeting Held On August 13, 2024
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Unaudited Financial Results for the quarter ended June 30, 2024, along with the Limited Review Reports on the aforesaid results as issued by the B S R & Co. LLP, Chartered Accountants, Auditors of the Company, enclosed as Annexure A. Press Release outlining key updates on the aforesaid results are enclosed as Annexure B. Emcure Pharmaceuticals Ltd - 544210 - Board Meeting Outcome for Outcome Of Board Meeting Held On August 13, 2024
The Board of Directors of the Company at its meeting held today i.e. Tuesday, August 13, 2024 has inter-alia approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024, as reviewed and recommended by the Audit Committee. Pursuant to Regulation 33 of the Listing Regulations, we are enclosing herewith the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024, along with the Limited Review Reports on the aforesaid Results as issued by B S R & Co. LLP, Chartered Accountants, Auditors of the Company, enclosed as Annexure A. Press Release outlining key updates on the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024, is also enclosed herewith as Annexure B. Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 read with Para A of Part of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform that CARE Ratings Limited ("CARE"), has upgraded its ratings on the Bank Facilities of Emcure Pharmaceuticals Limited ("the Company"), vide its press release as received by the Company on August 13, 2024. Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2025, as amended, we wish to inform that CRISIL Ratings Limited ("CRISIL") has upgraded its ratings on the Bank Loan Facilities of Emcure Pharmaceuticals Limited. Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation for Earnings Call for Investors/ Analysts to be held on Wednesday, August 14, 2024 at 8.30 a.m. (IST) to discuss the Company''s unaudited financial results (standalone and consolidated) and performance for the quarter ended June 30, 2024. Emcure Pharmaceuticals Ltd - 544210 - Board Meeting Intimation for Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30, 2024
Emcure Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 ,inter alia, to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2024.